Overview

This trial is active, not recruiting.

Condition breast cancer.
Treatment prone and supine simulation
Sponsor Vincent Vinh-Hung
Collaborator Varian Medical Systems
Start date September 2010
End date April 2013
Trial size 280 participants
Trial identifier NCT02237469, HUG 13-184R

Summary

The study purpose is to evaluate whether or not clinical characteristics of women with breast cancer can predict which position for radiation treatment, prone or supine, will be associated with a dosimetry gain. Dosimetry gain in this study means the lowest radiation dose to non-target organs (heart, lungs, contralateral breast), while giving the prescribed dose to tumor bed and ipsilateral breast.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective
Arm
Women with breast cancer receiving simulation in prone and in supine position for adjuvant radiation treatment.
prone and supine simulation
Treatment planning in the two positions.

Primary Outcomes

Measure
Radiation dose to heart and lungs
time frame: 4 months

Secondary Outcomes

Measure
Radiation dose to tumor bed and ipsilateral breast
time frame: 4 months

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Breast conserving surgery - Adjuvant radiation treatment - Simulation done prone and supine Exclusion Criteria: - Simulation in only one position

Additional Information

Official title Retrospective Dosimetric Study of Prone Radiotherapy for Breast Cancer
Principal investigator Vincent Vinh-Hung, MD, PhD
Description Retrospectively identify women who received curative radiation treatment after breast conserving cancer surgery, in whom simulation in prone and in supine position was performed. Compare the treatment plans for doses to targets and to non-target organs, according to clinical parameters of body mass index, size of breast, location of tumor and side. Furthermore, evaluate whether a single CT slide is enough or not to predict a dosimetry advantage.
Trial information was received from ClinicalTrials.gov and was last updated in September 2014.
Information provided to ClinicalTrials.gov by University Hospital, Geneva.